Page 602«..1020..601602603604..610620..»

HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeting

Posted: November 8, 2021 at 2:33 am

HONG KONG, Shanghai and FLORHAM PARK, N.J., Nov. 07, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new analyses and updates on the ongoing studies of HMPL-523 and HMPL-306 will be presented at the upcoming 63rd American Society for Hematology’s (ASH) Annual Meeting and Exposition, taking place on December 11-14, 2021. The meeting will be held virtually and in person at the Georgia World Congress Center in Atlanta, Georgia US.

Read more here:
HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeting

Posted in Global News Feed | Comments Off on HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeting

CLINUVEL Expands Pharmaceutical Portfolio

Posted: November 8, 2021 at 2:33 am

Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative disorders Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative disorders

Here is the original post:
CLINUVEL Expands Pharmaceutical Portfolio

Posted in Global News Feed | Comments Off on CLINUVEL Expands Pharmaceutical Portfolio

AS AB CITY starts the mandatory buy-back of AS Olainfarm shares

Posted: November 8, 2021 at 2:33 am

In accordance with a decision by the majority of shareholders at the AS Olainfarm Extraordinary Meeting of Shareholders held on 14 October 2021, AS Olainfarm shares are being delisted from the regulated market, and the company’s shares will no longer be traded on the NASDAQ Riga Stock Exchange. In order to ensure that AS Olainfarm shareholders have the opportunity to receive fair value for their shares, the mandatory buy-back of AS Olainfarm shares is currently taking place. It is being conducted in accordance with the provisions of the Republic of Latvia’s Financial Instrument Market Law, and is being overseen by the Financial and Capital Market Commission (FCMC).

Read the original post:
AS AB CITY starts the mandatory buy-back of AS Olainfarm shares

Posted in Global News Feed | Comments Off on AS AB CITY starts the mandatory buy-back of AS Olainfarm shares

Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and…

Posted: November 8, 2021 at 2:33 am

– One of the largest private financings of a UK biotech company, and the largest from a single source – continues Blackstone conviction in the country

The rest is here:
Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and...

Posted in Global News Feed | Comments Off on Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and…

QuantuMDx secures £15 million equity investment from Vita Spring and enters into Cooperation Agreement discussions with Sansure Biotech

Posted: November 8, 2021 at 2:33 am

QuantuMDx secures £15 million equity investment from Vita Spring and enters into Cooperation Agreement discussions with Sansure Biotech

Read this article:
QuantuMDx secures £15 million equity investment from Vita Spring and enters into Cooperation Agreement discussions with Sansure Biotech

Posted in Global News Feed | Comments Off on QuantuMDx secures £15 million equity investment from Vita Spring and enters into Cooperation Agreement discussions with Sansure Biotech

Lab-Growing Everything Might Be The Only Way To Attain A Sustainable World – Intelligent Living

Posted: November 8, 2021 at 2:33 am

Our Need For Things Lab-Grown

What was once something of the movies objects forming themselves in thin air is real now. Various things can be grown in a laboratory setting, some even on a large scale for commercial distribution. This technology could be a big part of the solution to establish sustainable societies. At the moment, we harvest organs from the deceased, rear animals for meat and dairy, destroy forests by cutting down trees for wood, mine the earth for diamonds, and the list goes on. All these things can already be lab-made or are on the brink of reality.

Once these staples of society can be mass-made affordably, they could supply the world while minimally impacting the natural environment. Acres of land wouldnt need to be used for food and building materials, meaning deforestation can cease, for starters. Looking at lab-grown meats alone: they require 99% less land than traditionally farmed meats, generate up to 96% fewer emissions, use up to 96% less water, and no animals need to be slaughtered in the process.

Naturally, there will be short-term disruptions, particularly job-related. For example, eco-friendly agriculture will mean fewer farms and agriculture jobs. But new employment opportunities will emerge in the scientific and technical fields related to lab-grown foods.

Whats the difference between 3D printing (additive manufacturing) and lab-grown, you may be wondering? 3D printing uses material as ink anything from plastic to cellular material whereas lab-grown materials start off as a bit of material that multiplies on its own, replicating natural processes. Thus, lab-grown material has the same cellular structure as the naturally occurring material and mimics the natural formation process but within a much shorter period.

In the future, we are bound to see various lab-grown breakthroughs coming from the medical field. Eventually, there should be alternative sources for organs and blood cultured from stem cells. In addition, there will likely be lab-produced medicines (lotions, ointments, balms, nutraceuticals, energy drinks, etc.), breast milk, and more.

Scientists are well on the way to functioning full-sized organs, with several innovations in fully functional mini-organs, or organoids, making headlines in recent years. For now, these organoids are tools for testing new drugs and studying human diseases. But soon enough, these research teams will take the technology to the next level and develop organs that can be used for implantation when someone needs an organ replacement. So far, the brain, liver, lungs, thymus, heart, blood, and blood vessels are among the growing list of lab-grown medical accomplishments.

A team of scientists from the University of Pittsburgh managed to grow miniature human livers using induced pluripotent stem cells (IPSCs) made from human skin cells. Meaning, in the far future, someone needing a liver transplant could have the organ grown from their own skin cells! This method may even reduce the chances of a patients immune system rejecting the new tissue because it would recognize the cells as self. Whats more, their lab-grown livers matured in under a month compared to two years in a natural environment.

The scientists tested their fully-functional mini-livers by transplanting them into rats. In this proof-of-concept study, the lab-made organs survived for four days inside their animal hosts, secreting bile acids and urea like a healthy liver would.

A research team led by the University Hospital Dsseldorf induced pluripotent stem cells (iPSCs) to grow into pea-sized brain organoids with rudimentary eye structures that sense light and send signals to the rest of the brain. They used skin cells taken from adult donors, reverted them back into stem cells, and placed them into a culture mimicking a developing brains environment, which encourages them to form specific brain cells. Their mini-brains grew optic cups, vision structures of the eye found where the optic nerve and retina meet. The cups even grew symmetrically, as eyes would, and were functional!

Jay Gopalakrishnan, a senior author of the study, said:

Our work highlights the remarkable ability of brain organoids to generate primitive sensory structures that are light sensitive and harbor cell types similar to those found in the body. These organoids can help to study brain-eye interactions during embryo development, model congenital retinal disorders, and generate patient-specific retinal cell types for personalized drug testing and transplantation therapies.

This achievement is the first time an in vitro system shows nerve fibers of retinal ganglion cells reaching out to connect with their brain target an essential aspect of the mammalian brain.

Scientists from Michigan State University developed functional miniature human heart models grown from stem cells complete with all primary heart cell types and with functioning chambers and vascular tissue. The models could help researchers better understand how hearts develop and provide an ethical platform for treating disease and testing drugs or new treatments.

The teams lab-grown mini hearts follow the fetal development of a human heart, offering a new view into that process. The organoids start beating by day six, and they grow into spheres approximately 1 mm (0.4 in) wide, with all significant cardiac cell types and multiple internal chambers by day 15.

Aside from research purposes, full-sized lab-grown hearts could solve the shortage problem of hearts the world faces today. More than 25 million people suffer heart failure each year. In the United States, approximately 2,500 of the 4,000 people in line for heart transplants receive them. That means almost 50% of the people needing a new heart to keep them alive wont get it.

Unlimited supplies of blood for transfusions are possible with lab-growing technology. Blood has been challenging to grow in the lab. However, real breakthroughs in creating artificial blood have sprung up!

A couple of years ago, Japanese researchers developed universal artificial blood that worked for all blood types. It even has a shelf life of one year stored at room temperature, therefore eliminating the problem of identifying blood type and storage simultaneously.

Like that wasnt impressive enough, last year, a team of scientists from the South China University of Technology, the University of New Mexico, and Sandia National Laboratories created artificial red blood cells (RBCs) with more potential capabilities than real ones! The synthetic RBCs mimic the properties of natural ones such as oxygen transport, flexibility, and long circulation times with the addition of a few new tricks up their sleeves, such as toxin detection, magnetic targeting, and therapeutic drug delivery. In addition, blood contains platelets and red blood cells, so these new cells could be used to make superior artificial blood.

Researchers from the University of British Columbia successfully coaxed stem cells to grow into human blood vessels. The thing that is so remarkable about this study is that the system of blood vessels grown in the lab is virtually identical to the ones currently transporting blood throughout the body. They are using this now to generate new leads in diabetes treatment. They put the lab-grown blood vessels in a petri dish designed to mimic a diabetic environment.

The global demand for meat and dairy is expected to rise by almost 90% over the next 30 years, regardless of the need to cut back on meat consumption. The risk of environmental damage and the rising food demand itself is a problem many have recently addressed. Thats why companies worldwide are on the verge of scaling up all sorts of lab processes to produce various food items, including steaks, chicken, cheese, milk, ice cream, fruits, and more.

Thinktank RethinkX even published research suggesting that proteins from precision fermentation (lab-grown protein using microbes) will be about ten times cheaper than animal protein by 2035, resulting in a collapse of the livestock industry. It says the new food economy will subsequently:

replace an extravagantly inefficient system that requires enormous quantities of inputs and produces considerable amounts of waste with one that is precise, targeted, and tractable. [Using tiny land areas, with a massively reduced requirement for water and nutrients, it] presents the most significant opportunity for environmental restoration in human historyFarm-free food offers hope where hope is missing. We will soon be able to feed the world without devouring it.

The worlds pace of meat consumption is placing a significant strain on the environment. Many studies show that eating less meat is just as crucial to slowing down global warming as using solar panels and zero-emissions vehicles. Unfortunately, animal farming generates an obscene amount of greenhouse gas emissions. Yet again, scientists come to the rescue, working diligently to fix this situation.

Over a decade ago, researchers created something akin to ground beef, but the complex structure of steak didnt happen until recently, with Aleph Farms debuting its thick-cut rib-eye steak in 2018. Furthermore, that first burger cost around US$345,000, but now the price has dropped dramatically to the point that lab-grown chicken is to be commercially produced and hit grocery store shelves as of this year.

SuperMeat, Eat Just, and Aleph Farms are todays most prominent startups working on getting lab-grown meats to people looking to lower their carbon and environmental footprints. In addition, their products are made from actual animal cells, so theyre real meat, but no animals had to be hurt or killed.

Speaking of Aleph Farms, the company also grew meat in space to show that it can even be done in a zero-gravity environment with limited resources.

Aside from Aleph Farms figuring out how to make steak like an authentic steak, a group of Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) researchers also devised a solution to the texture challenge. First, they made edible gelatin scaffolds that have the texture and consistency of real meat. Then, they grew rabbit and cow muscle cells on this scaffolding. The research demonstrates how realistic meat products are possible!

Parker and his Disease Biophysics Group developed a technique to produce the scaffolding. Its a fiber-production system inspired by cotton candy known as immersion Rotary Jet-Spinning (iRJS). It enabled the team to spin long nanofibers of a specific shape and size using centrifugal force. So, they spun food-safe gelatin fibers, creating the base upon which cells could grow.

Natural muscle tissue is composed of an extracellular matrix, which is the glue that holds the tissue together. As a result, it contributes to the texture of the meat. The spun gelatin fibers mimicked this extracellular matrix and provided the texture to make the lab-grown meat realistic. When the team seeded the fibers with animal (rabbit and cow) muscle cells, they anchored to the gelatin scaffolding and grew in long, thin structures, similar to real meat.

Meanwhile, Boston College developed a new, even greener technology that uses the skeleton of spinach leaves to support bovine animal protein growth. However, animal products arent eliminated from the process entirely. For example, lab-grown steak and chicken are created by painlessly harvesting muscle cells from a living cow, subsequently fed and nurtured to multiply and develop muscle tissue. But for this to have the same texture as real meat, the cells need structural support to flourish and are therefore placed in a scaffold.

Singapore is leading the way, becoming the first country in the world to approve the sale of Eat Justs cultured chicken. The company will start by selling nuggets at a restaurant. Meanwhile, SuperMeat has been handing out lab-grown chicken burgers in Israel for free. Theyre aiming to gain public acceptance of the idea.

The cultured chicken starts as a tiny number of harvested cells. Those cells are put into a bioreactor and fed the same nutrients the living animal would consume to grow. The cells multiply and turn into an edible portion of cultured chicken meat. The meats composition is identical to that of real chicken and offers the same nutritional value. And its cleaner because its antibiotic-free!

Labs are manufacturing dairy products by utilizing the fermentation process of living microbes to produce dairy proteins like whey and casein. These proteins are then used to make dairy products like butter, cheese, and ice cream. Two leading companies in this category are Imagindairy and Perfect Day, which already have several products on supermarket shelves in the United States.

Researchers havent figured out how to make fruits and vegetables yet, but a team is perfecting a cell cultivation process that generates plant biomass. The stuff tastes like the natural-grown product from which the cells were obtained and even exceeded its nutritional properties. Although, the texture of the biomass is different. For example, an apple isnt a solid apple akin to one grown from a tree. Instead, its like applesauce.

Lab-produced materials Including wood, diamonds, leather, glass, clothing, crystals, gels, cardboard, and plastics for making objects are either under development or already available. Many materials need to be taken from nature mined from the earth or cut down from forests. If they can be made in a lab instead, then people could leave nature alone!

A recent project led by a Ph.D. student at MIT paves the way for lab-grown wood one of the worlds most vital resources used to make paper, build houses, heat buildings, and so much more. The process begins with live plant cells cultivated in a growth medium coaxed using plant hormones to become wood-like structures. Next, a gel matrix is used to guide the shape of the cellular growth, and controlling the levels of plant hormones regulates the structural characteristics. Therefore, the technology could grow anything from tables and chairs to doors to boats and so on.

The environmental and socio-economic impact of traditionally mined diamonds has been exposed in recent years, and as awareness grows, the rising popularity of lab-grown diamonds does too. Mined diamonds are linked to bloody conflicts, and their excavation produces carbon emissions, requires substantial water use, and causes severe land disturbances.

Research has found that 1,000 tons of earth have to be shifted, 3,890 liters or more of water is used, and 108kg of carbon is emitted per one-carat stone produced. In addition, the traditional diamond mining industry causes irreversible damage to the environment, hence why, a decade ago, researchers started experimenting with how to grow them in the lab. Its been a feat a long time in the making, but we finally have lab-grown diamonds available for eco-conscious consumers to buy.

Diamonds are made of pure carbon. It takes extreme heat and pressure for carbon to crystalize. In nature, this happens hundreds of miles beneath the Earths surface. The ones being mined were shot out by a volcano millions of years ago. So how have scientists managed to hack such an intense and time-consuming process?

They began by investigating the mechanisms behind the diamond formation, zooming in at the atomic level. This led to the invention of a novel technology that utilizes the process of HPHT (high pressure, high temperature) to mimic the natural atmospheric conditions of diamond formation. Labs can use it to replicate the process and turn pure carbon into diamonds in 2-6 weeks.

Lab-grown gems are eco-friendly rocks, especially when theyre made entirely from the sky, like SkyDiamonds. Even the electricity used to grow its stones is from renewables, so theyll indeed be the worlds first zero-impact diamonds.

But how are the diamonds created out of thin air? They are made of carbon from the sky and rainwater. The sky mining facility is in Stroud. Energy is sourced from wind and sunlight. The CO2 is sourced directly from the air. Hydrogen is produced by splitting rainwater molecules in an electrolysis machine using renewable energy. The captured carbon and hydrogen are then used to make methane, used to grow the diamonds. The final product is a diamond anatomically identical to those mined from the ground. It is even accredited, fully certified, and graded by the International Gemological Institute.

Another company, Climeworks, is also making diamonds using carbon sucked from the sky. However, SkyDiamonds takes it a step forward by using rainwater and sunshine in the process.

The last lab-grown object were going to discuss is not something in the works, but an idea a fantastic and outlandish one thats jumping far into the future but was thought up in 2010 by Mercedes Benz. The luxury car companys ambitious BIOME idea shows just how wild imagination can get with lab-grown technology. It envisions a day when it can grow an entire supercar from scratch.

Mercedes-Benz explained when launching the concept:

The interior of the BIOME grows from the DNA in the Mercedes star on the front of the vehicle, while the exterior grows from the star on the rear. The Mercedes star is genetically engineered in each case to accommodate specific customer requirements, and the vehicle grows when the genetic code is combined with the seed capsule. The wheels are grown from four separate seeds.

This list of lab-grown possibilities is just the tip of the iceberg! Other materials in the pipeline include leather, chocolate, and silk. This intelligent technology can make anything a scientist can dream up! The only limit is the imagination and dedication of brilliant people.

Excerpt from:
Lab-Growing Everything Might Be The Only Way To Attain A Sustainable World - Intelligent Living

Posted in Michigan Stem Cells | Comments Off on Lab-Growing Everything Might Be The Only Way To Attain A Sustainable World – Intelligent Living

Duke Faculty Promoted or Appointed to the Rank of Full Professor – Duke Today

Posted: November 8, 2021 at 2:33 am

Congratulations to our Duke faculty who have been promoted or appointed to the rank of fullprofessor. Promotion and appointment to full professor is the culmination of a rigorous review by the facultys academic peers inside and outside Duke and by the academic leaders at the department, schooland campus levels. The review process looks for distinction and impact in research, teaching, serviceand engagement, and for leadership in the facultys area of expertise nationally and internationally. All these colleagues embody and exemplify the academic excellence that is so essential to fulfilling Dukes mission of education, discoveryand engagement. Congratulations!

Francesco BianchiProfessor of EconomicsFrancesco Bianchi is a professor of economics in the Trinity College of Arts & Sciences and a research professor at Johns Hopkins University for the 2021-2022 academic year. He is a member of the Center for Economic and Policy Research and the National Bureau of Economic Research and an associate editor of the Journal of Monetary Economics, Quantitative Economics and the Journal of Applied Econometrics. Bianchi received his Ph.D. in economics from Princeton University in 2009. He has held visiting positions at the University of California at Los Angeles, New York University, University of Pennsylvania and Northwestern University. In 2015 he was awarded the Wim Duisenberg Research fellowship and in 2010 he received the Zellner Thesis Award in Business and Economic Statistics. He has published in the American Economic Review, the Review of Economic Studies, the Review of Economics and Statistics, The Journal of Monetary Economics and other leading academic journals. Currently, Bianchis main research interests involve the role of agents beliefs in explaining macroeconomic dynamics, the interaction between monetary and fiscal policyand macro-finance.Appointment Date: July 1, 2021

Mark Edward BorsukProfessor of Civil and Environmental EngineeringMark Borsuks research concerns the development and application of mathematical models for integrating scientific information on natural, technical, and social systems. He is a widely-cited expert in Bayesian network modeling with regular application to environmental and human health regulation and decision making. He is also the originator of novel approaches to climate change assessment, combining risk analysis, game theory, and agent-based modeling. Borsuks highly collaborative research has been funded by NSF, EPA, NIH, NIEHS and USFS, and he has authored or co-authored 75 peer-reviewed journal publications and 6 book chapters. Borsuk received the Chauncey Starr Distinguished Young Risk Analyst Award from the Society for Risk Analysis in 2013 and the Early Career Research Excellence Award from the International Environmental Modelling and Software Society in 2008. Before joining the Duke faculty, Dr. Borsuk was a member of the Dartmouth College faculty for 10 years where he held an appointment in the Thayer School of Engineering. Dr. Borsuk received a B.S.E. in Civil Engineering and Operations Research from Princeton University, an M.S. in Statistics and Decision Sciences from Duke University, and a Ph.D. in Environmental Science and Policy from Duke University. He did his post-doctoral training in the Department of Systems Analysis, Integrated Assessment, and Modelling (SIAM) at the Swiss Federal Institute for Aquatic Science and Technology (EAWAG), where he advanced to head of the Decision Analysis and Integrated Assessment group. As part of his appointment at Duke, Dr. Borsuk directs a new interdisciplinary research and teaching initiative in risk, uncertainty, optimization and decision-making.Appointment Date: July 1, 2021

Kenneth BrownProfessor of Electrical and Computer EngineeringKenneth Brown is professor of electrical and computer engineering in the Pratt School of Engineering and physics in the Trinity College of Arts & Sciences. His research interests include the control of quantum systems for both understanding the natural world and developing new technologies. His current research areas focus on the development of the robust quantum computers and the study of molecular properties at cold and ultracold temperatures. Awards include being a Fellow of the American Physical Society, an Experienced Research Fellow with the Alexander von Humboldt Foundation and a Kavli Fellow with the Kavli Foundation and National Academy of Science. Brown earned his B.S. from the University of Puget Sound and Ph.D. from the University of California at Berkley.Appointment Date: January 1, 2021

Frank BruniEugene C. Patterson Professor of the Practice of Journalism and Public PolicyFrank Bruni is the Eugene C. Patterson Professor of the Practice of Journalism and Public Policy in the Sanford School of Public Policy. He joined the Duke faculty in 2021 after 25 years at the New York Times, where he served as metro reporter, White House correspondent, Rome bureau chief, chief restaurant critic and most recently as an Op-Ed columnist. He was the first openly gay Op-Ed columnist at the Times and in 2016 was honored by the National Lesbian and Gay Journalists Association with the Randy Shilts Award for his lifetime contribution to LGBTQ equality. He is the author of three New York Times best sellers: a 2015 examination of the college admissions frenzy, Where You Go Is Not Who Youll Be; a 2009 memoir, Born Round, about the joys and torments of his eating life; and a 2002 chronicle of George W. Bushs initial presidential campaign, Ambling into History. His first cookbook, A Meatloaf in Every Oven, was published in February 2017 and co-written with his Times colleague Jennifer Steinhauer. His forthcoming book, The Beauty of Dusk: On Vision Lost and Found, which reflects on his imperiled eyesight and the challenges of aging, will be published in March 2022. Bruni joined the Times from the Detroit Free Press, where he was, alternately, a war correspondent, the chief movie critic and a religion writer. He has worked as a general-assignment writer for the Detroit Free Press and the New York Post. He has taught at Princeton University and been active at his alma mater, University of North Carolina at Chapel Hill, as an advisor on improving the undergraduate experience and the liberal arts curriculum.Appointment Date: May 13, 2021

Stephen BuckleyEugene C. Patterson Professor of the Practice of Journalism and Public PolicyStephen Buckley is the Eugene C. Patterson Professor of the Practice of Journalism and Public Policy in the Sanford School of Public Policy. He is a veteran editor and educator who worked atThe Washington Post, Tampa Bay Timesand the Poynter Institute. He joined the Duke faculty in July 2021. Buckley, a 1989 Duke graduate in political science, has had a wide-ranging career as a local reporter, foreign correspondent, editor and journalism educator. After graduating from Duke, Buckley spent 12 years at The Post as a local reporter and foreign correspondent.He covered education, courts and the night police beat and then became a foreign correspondent, initially as thePostsAfrica Bureau Chief and then the papers first correspondent based in Brazil. He returned to St. Petersburg, Florida in 2001 as a national reporter for theTimesand then became an editor in charge of national and international coverage before being promoted to managing editor and then publisher of tampabay.com, the papers digital site. He moved to the Poynter Institute in 2010 as dean of the faculty. In 2015, he moved to Kenya, where he taught at The Aga Khan University before becoming the lead story editor forGlobal Press Journal, an international news organization that focuses its reporting on under-covered regions.Appointment Date: May 13, 2021

M. Kate BundorfJ. Alexander McMahon Distinguished Professor of Health Policy and ManagementM. Kate Bundorf is J. Alexander McMahon Distinguished Professor of Health Policy and Management in the Sanford School of Public Policy. Her research focuses on health policy and the economics of health care systems. She has studied public and private health insurance markets, the organization of health care providers and consumer decision making in health care. Prior to joining the faculty at Duke, Bundorf wasan associate professor of health research and policy at the Stanford University School of Medicine. She is also a faculty research fellow at the National Bureau of Economic Research, the President-Elect of ASHEcon and a co-editor of The Journal of Health Economics. Bundorf received her M.B.A. and M.Ph. from The University of California at Berkeley and her Ph.D. from The Wharton School. She was a Fulbright Lecturer at Fudan School of Public Health in Shanghai, China during 2009 and 2010. Her research has been published in leading economic and health policy journals and has received funding from the U.S. National Institutes of Health, the Agency for Health Care Research and Quality and the Robert Wood Johnson Foundation. She received the 13th Annual Health Care Research Award from The National Institute for Health Care Management in 2007.Appointment Date: January 1, 2021

Daniel CasteloWilliam Kellon Quick Professor of Theology and Methodist StudiesDaniel Castelo is the William Kellon Quick Professor of Theology and Methodist Studies in the Divinity School. During his doctoral work, he taught intensive Wesleyan theology courses in Mexico, Honduras and Brazil and afterward took a teaching post at a Mexican seminary for three years. Subsequently, he moved to the Pacific Northwest, where he taught dogmatic and constructive theology at Seattle Pacific University for fourteen years. Castelo has been an active participant in the Central American Methodist Course of Study program and recently has served as a doctoral mentor for the Hispanic Theological Initiative. He began his publishing career exploring the topic of divine attribution. This work resulted in the monographThe Apathetic God, for which he won a John Templeton Award for Theological Promise. He proceeded to consider questions surrounding a Christian account of theodicy, the doctrine of God broadly, and the theological interpretation of Scripture. Additionally, he has focused on the theology of renewal movements and Christian pneumatology. He currently has publishing contracts for books that explore Latinx theology and a Wesleyan doctrine of God.Appointment Date: July 1, 2021

Mine etinkaya-RundelProfessor of the Practice of Statistical ScienceMine etinkaya-Rundel is professor of the practice and director of undergraduate studies in the Department of Statistical Science. She is also an affiliated faculty in theComputational Media, Artsand Culturesprogram at Duke University. Her work focuses on innovation in statistics and data science pedagogy, with an emphasis on computing, reproducible research, student-centered learning and open-source education. etinkaya-Rundel works on integrating computation into the undergraduate statistics curriculum, using reproducible research methodologies and analysis of real and complex datasets.Appointment Date: July 1, 2021

Joel CollierProfessor of Biomedical EngineeringJoel Collier is professor of biomedical engineering in the Pratt School of Engineering. His research specialty is in immune engineering, a new but rapidly growing field in which bioengineering approaches are used to modulate the immune system. He has made important contributions in self-assembling peptides and their application in vaccine development and cell delivery, particularly relevant in the COVID-19 pandemic. In addition to his impressive research record, he has worked tirelessly to improve the departments student experience, supporting student-initiated efforts to discuss the impact of social issues on student life and strengthening the undergraduate and graduate biomaterials curriculum with the creation of two well-received courses he created. Collier earned his Ph.D. from Northwestern University.Appointment Date: January 1, 2021

Shaundra DailyProfessor of the Practice of Electrical & Computer Engineering and Computer ScienceShaundra Daily is professor of the practice of electrical and computer engineering in the Pratt School of Engineering and computer science in the Trinity College of Arts & Sciences. Prior to joining Duke, she was an associate professor with tenure at the University of Florida in the Department of Computer & Information Science & Engineering. She also served as an associate professor and interim co-chair in the School of Computing at Clemson University. Her research focuses on the design, implementation, and evaluation of technologies, programs, and curricula to support diversity, equity, and inclusion in STEM fields. Her approach has focused on three key strategies: 1) Utilizing technology to support the development of interpersonal skills that will facilitate collaboration in diverse settings; 2) Developing technologies and programs geared towards making computing and engineering accessible to diverse identities; and 3) Mentoring, developing outreach, and researching the experiences of marginalized groups in computing and engineering. Having garnered over $43M in funding from public and private sources to support her research activities, Dailys work has been featured in USA Today, Forbes, National Public Radio, and the Chicago Tribune. Daily earned her B.S. and M.S. in Electrical Engineering from the Florida Agricultural and Mechanical University Florida State University College of Engineering, and a S.M. and Ph.D. from the MIT Media Lab.Appointment Date: July 1, 2021

Ofer EldarProfessor of LawOfer Eldar is a professor at the Duke University School of Law, where he teaches business associations and corporate governance. He also holds secondary faculty appointments at the Duke economics department and the Duke Fuqua School of Business, and he serves as a research fellow of the Duke Innovation & Entrepreneurship Initiative. His research interests include corporate governance, corporate finance, entrepreneurship, financial regulation, and business organizations. Prior to joining the Duke Law faculty, Eldar was the Wagner Fellow in Law & Business at the NYU Stern School of Business. His scholarship has appeared in leading economics, finance, and law journals, and featured in various major media outlets. Eldar earned his Ph.D. in financial economics from Yale University, and a J.S.D. from Yale Law School, where he was a Kauffman Fellow in Law & Economics. He practiced corporate law at Freshfields Bruckhaus Deringer in London, and at Weil, Gotshal & Manges in New York.Appointment Date: July 1, 2021

Sina FarsiuProfessor of Biomedical EngineeringSina Farsiu is a professor of biomedical engineering in the Pratt School of Engineering and a professor of ophthalmology in the School of Medicine. He is also the director of the Vision and Image Processing (VIP) Laboratory. His laboratory develops advanced machine learning and biophotonics imaging tools to improve the health of young children and adults with ocular and neurological diseases (e.g., age-related macular degeneration, diabetic retinopathy, Alzheimer, retinopathy of prematurity, and ALS). He earned his B.Sc. from the Sharif University of Technology in Iran, his M.Sc. from the University of Tehran, and his Ph.D. from the University of California at Santa Cruz. He is a Fellow of IEEE, SPIE, OSA and AIMBE.Appointment Date: January 1, 2021

Lisa GennetianPritzker Professor of Early Learning Policy StudiesLisa Gennetian is Pritzker Professor of Early Learning Policy Studies in the Sanford School of Public Policy. She is an applied economist whose research straddles a variety of areas concerning child poverty from income security and stability to early care and education with a particular lens toward identifying causal mechanisms underlying how child poverty shapes childrens development. She is a co-PI on the first multi-site multi-year randomized control study of a monthly unconditional cash transfer to low income mothers of infants in the U.S. called Babys First Years. Her recent work bridges poverty scholarship with a behavioral economic framework.The Persistence of Poverty in the Context of Economic Instability: A Behavioral Perspective, describes such a framework for poverty programs and policy, co-authored with Dr. Eldar Shafir and her co-authored publication Behavioral Economics and Developmental Science, further advances the application of behavioral economic insights to the arena of childrens development. She has also co-edited a volume with scholar Marta Tienda for the ANNALS of the American Academy of Political and Social Science titled Investing in Latino Children and Youth. Gennetian has since launched the beELL initiative; applying insights from behavioral economics to design strategies to support parent and family engagement in, and enhance the impacts of, existing childhood interventions. Dr. Gennetian also has a body of research examining poverty among Latino children and families, serving as a PI on several grants and a co-PI directing work on poverty and economic self-sufficiency at the National Center for Research on Hispanic Families.Appointment Date: July 1, 2021

Charles GersbachJohn W. Strohbehn Distinguished Professor of Biomedical EngineeringCharles Gersbach is the John W. Strohbehn Distinguished Professor of Biomedical Engineering in the Pratt School of Engineering. He is also the director of the Duke Center for Biomolecular and Tissue Engineering and the director of the Duke Center for Advanced Genomic Technologies. He received his Ph.D. in biomedical engineering from the Georgia Institute of Technology and completed postdoctoral training at The Scripps Research Institute. His research interests are in genome and epigenome editing, gene therapy, regenerative medicine, biomolecular and cellular engineering, synthetic biology and genomics. His work has led to new approaches to study genome structure and function, program cell biology, and treat genetic disease. Gersbachs work has been recognized through awards including the National Institutes of Health Directors New Innovator Award, the National Science Foundation CAREER Award, the Outstanding New Investigator Award from the American Society of Gene and Cell Therapy, the Allen Distinguished Investigator Award, and induction as a Fellow of the American Institute for Medical and Biological Engineering. He is also the co-founder of three biotechnology companies and an advisor to several others.PAppointment Date: January 1, 2021

Steven HaaseProfessor of BiologySteven Haase is professor of biology in the Trinity College of Arts & Sciences. His research group interests focus on understanding the biological clock mechanisms controlling cell division and host-pathogen interactions. His research receives funding from the National Institutes of Health, National Science Foundation, and the Defense Advanced Research Projects Agency. Haase is the senior author on a recent Science paper, entitled An intrinsic oscillator drives the blood stage cycle of the malaria parasitePlasmodium falciparum, and has published in several prestigious journals. He earned his B.S. from Colorado State University and Ph.D. from Stanford University.Appointment Date: July 1, 2021

Kerry HaynieProfessor of Political ScienceKerryL.Haynieisprofessor and chair of political science, professor of African & African American studies,and a former chair of Dukes Academic Council(Faculty Senate), 2019-21. He earned B.A. and Ph.D. degrees from the University of North Carolina at Chapel Hill, and a masters degree from theGraduate School of Public and International Affairs at theUniversity of Pittsburgh. Before coming to Duke in 2003, Haynie was a member of the facultyat Rutgers, The State University of New Jersey, andthe University of Pennsylvania. Hayniesresearch examines how the underlying theory, structures, and practices of American political institutions affect African Americans and womens efforts to organize and exert influence on the political system.In 2012,he andhis co-author BethReingoldwere the co-winners of the American Political Science Associations Women and Politics Research Sections Best Paper Award.In addition to articles invarious academic journals,his publications include,Race, Gender, and Legislative Representation: Toward a More Intersectional Approach(with BethReingoldand KirstenWidner), winner of the 2021 Richard F. Fenno, Jr. Prize from the American Political Science Association for the best book in legislative studies.Appointment Date: July 1, 2021

Andrew Douglas HiltonProfessor of the Practice of Electrical and Computer EngineeringAndrew Douglas Hilton is professor of the practice of electrical and computer engineering in the Pratt School of Engineering. He is also Pratts Director of Innovation in Computing Education. His main focus is on teachingprofessional-level programming skills to ECEs master's students to prepare them for software engineering careers. Hilton teaches a 3-week introduction to Programming Python forDukes Master in Interdisciplinary Data Science, and Dukes Center for Computational Thinking. He has two Coursera specializations, one in Java and another in C. Hilton earned his Ph.D. from the University of Pennsylvania.Appointment Date: July 1, 2021c

Josh HuangProfessor of NeurobiologyJosh Huang is professor of neurobiology in the Basic Sciences division of the School of Medicine. His research combines multi-faceted approaches to study the organization, function, and assembly of brain circuits that orchestrate complex movements. His work receives funding from the National Institutes of Health. Huang joined Duke as faculty in 2020, after 20 years of research at the Cold Spring Harbor Laboratory in New York. He earned his Ph.D. from Brandeis University in Massachusetts.Appointment Date: March 1, 2021

Robin KirkProfessor of the Practice of Cultural AnthropologyRobin Kirk is professor of the practice of cultural anthropology in the Trinity College of Arts & Sciences. She is a faculty co-chair of theDuke Human Rights Center at the Franklin Humanities Instituteand is a founding member of thePauli Murray Project,an initiative of the center that seeks to use the legacy of this Durham daughter to examine the regions past of slavery, segregation and continuing economic inequality. An author and human rights advocate, she also directs the Human Rights Certificate. Her childrens book, Righting Wrongs: 20 Human Rights Heroes from around the World, will be published in 2022. Kirk is the author of "The Bond" fantasy trilogy, with a re-release of all three books scheduled for 2022. She's written three non-fiction books for adults, includingMore Terrible Than Death: Massacres, Drugs and Americas War in Colombia andThe Monkeys Paw: New Chronicles from Peru. She is a co-editor ofThe Peru Reader: History, Culture, Politics and co-edits Duke University Press World Readers series. An essayist and award-winning poet, she has published widely on issues as diverse as the Andes, torture, the politics of memory, family life and pop culture. Her essay on Belfast, City of Walls, is included in the Best American Travel Writing anthology of 2012. Kirk authored, co-authored and edited over twelve reports for Human Rights Watch, all available online. In the 1980s, Kirk reported for U.S. media from Peru, where she covered the war between the government and the Shining Path. She continues to write for US media, and has been published inThe New York Times, Washington Post, Sojourners, The American Scholar,theRaleigh News and Observer,theBoston Globe,theDurham Herald Sunand other media. She earned her M.F.A from Vermont College and B.A. from the University of Chicago.Appointment Date: July 1, 2021

Andrzej KosinskiProfessor of Biostatistics and BioinformaticsAndrzej S. Kosinski is professor of biostatistics and bioinformatics in the Basic Sciences Division of the School of Medicine. He is also a member of the Duke Clinical Research Institute (DCRI). His research interests include statistical methodology for evaluation of diagnostic tests, adjustment for misclassification, clinical trials, and analysis of observational data. Kosinskis research is funded by the National Institutes of Health, the Patient-Centered Outcomes Research Institute, the Society of Thoracic Surgeons, and the American Heart Association. He joined Duke faculty in 2003. He earned his M.Sc. from the University of Oxford in the United Kingdom and Ph.D. from the University of Washington in Seattle.Appointment Date: July 1, 2021

Tamar KushnirProfessor of Psychology and NeuroscienceTamar Kushnir is professor of psychology and neuroscience in the Trinity College of Arts & Sciences. Kushnir received her M.A. in Statistics and Ph.D. in Cognitive Psychology from the University of California at Berkeley, and was a postdoctoral fellow at the University of Michigan. Before coming to Duke, Kushnir was a professor at Cornell University in the department of Human Development and the co-director of the Cornell Cognitive Science Program.Kushnirswork is motivated by a long-standing curiosity aboutthe developing mind, in particular how childrenacquireabstract, coherentknowledge ofthe natural and social world from ordinary experiences.She has published on a range of topicsincluding how children use statistical patterns to infer causality, how we learn to detect trustworthy sources of knowledge, the developmental and cultural origins of our beliefs infree will and moral agency, how children learn and reason about social norms, and, most recently, the role ofimagination in social and moral cognition. In addition to scholarly publications, Kushnir maintains an active in communityengagement with local organizationsthat support young children and their families,especiallymuseums and other spaces that provide opportunities for playful learning. Kushnir has served as an associate editor at Child Development and theJournalCognitiveScience, is a member of the Moral Psychology Research Group, and currently serves on theboardof the Cognitive Development Society andas president-elect of the Society of Philosophy and Psychology.Appointment Date: July 1, 2021

Eric LaberProfessor of Statistical ScienceEric Laber is professor of statistical science in the Trinity College of Arts & Sciences and biostatistics and bioinformatics in the Basic Science Division of the School of Medicine. Labers research uses data to solve real-world problems in areas such as personalized medicine, human trafficking, sports, wildlife conservation and artificial intelligence. His work is funded by the National Institutes of Health, National Science Foundation, DOD, among others. Laber joined Duke in 2020, having held a faculty position at North Carolina State University prior to that. He earned his M.A. and Ph.D. from the University of Michigan at Ann Arbor.Appointment Date: January 1, 2021

Fan LiProfessor of Statistical ScienceFan Li is professor of statistical science in the Trinity College of Arts & Sciences with a secondary appointment at thedepartment of biostatistics and bioinformatics in the Basic Science Division of the School of Medicine. Her main research interest is causal inference designs and analysis for evaluating treatments and interventions in randomized experiments and observational studies, and their applications to health studies (also known as comparative effectiveness research) and computational social science. She also works on the interface between causal inference and machine learning. Lis research receives funding from the Burroughs Wellcome Fund, Patient Centered Outcomes Research Institute, National Institutes of Health, University of Notre Dame and the National Science Foundation. She joined Duke faculty in 2008. Li earned her B.S. from Peking University in China and Ph.D. from Johns Hopkins University.Appointment Date: July 1, 2021

David MacAlpineProfessor of Pharmacology and Cancer BiologyDavid MacAlpine is professor of pharmacology and cancer biology in the Basic Science Division of the School of Medicine. His laboratory is interested in understanding the mechanisms by which the molecular architecture of the chromosome regulates fundamental biological processes such as replication and transcription. Specifically, how replication, transcription and chromatin modification are coordinated on a chromosomal scale to maintain genomic stability. MacAlpines research is largely funded by the National Institutes of Health with previous funding from the American Cancer Society, Inc. He earned his Ph.D. from the University of Texas Southwestern Medical Centers Medical School.Appointment Date: January 1, 2021

Ryan McDevittProfessor of Business AdministrationRyan C. McDevitt is professor of business administration in the Fuqua School of Business with a secondary appointment in economics in the Trinity College of Arts and Sciences. Prior to joining Duke in 2013, he held faculty positions at the University of Rochesters Simon School of Business and Northwestern Universitys Kellogg School of Management. McDevitts work has been published in leading economics journals such as the American Economic Review, the Journal of Political Economy, the Quarterly Journal of Economics, and the Review of Economic Studies. His research is funded by the Washington Center for Equitable Growth, the National Science Foundation, and the National Bureau of Economic Research. He serves on advisory committees for the American Society of Nephrology and Renalogic. He has won teaching awards for his courses in economics, strategy, and econometrics. He earned his B.A from Williams College and Ph.D. from Northwestern University.Appointment Date: July 1, 2021

Cameron McIntyreProfessor of Biomedical EngineeringCameron McIntyre is professor of biomedical engineering in the Pratt School of Engineering and neurosurgery in the School of Medicine. His current research interests include Neural engineering, computational neuroscience, brain imaging and the design of human neuromodulation systems with special expertise in the biophysics of brain stimulation and recording. Prior to joining Duke in 2021, McIntyre held a faculty position at the Cleveland Clinic Foundation in 2003 and maintained a laboratory until 2012. In 2013 he moved his lab to the Case Western Reserve University to create the Case Neuromodulation Center. The current McIntyre Laboratory hopes to improve deep brain stimulation (DBS) for the treatment of movement disorders and provide the fundamental technology necessary for the effective application of DBS to new clinical arenas. He earned his B.S. and Ph.D. from Case Western Reserve University and held postdoctoral training at both Johns Hopkins University and Emory University.Appointment Date: July 1, 2021

Louise MeintjesProfessor of MusicLouise Meintjes is professor of music and cultural anthropology in the Trinity College of Arts & Sciences. Her book Sound of Africa! Making Music Zulu in a South African Studio is an ethnography of a recording studio in Johannesburg in the early 1990s, a time of tumultuous political transition and musical innovation in South Africa.In her most recent book, "Dust of the Zulu: Ngoma Aesthetics after Apartheid," Meintjestraces the political and aesthetic significance of ngoma, a competitive form of Zulu mens dance and music that emerged out of the legacies of colonialism and apartheid in South Africa. Contextualizing this performance practice within South Africa's history of violence, migrant labor, the HIV epidemicand the world music market, she follows a community ngoma team and its professional subgroup during the 20 years after apartheid's end. Meintjes earned her Hons-B.Mus. from the University of Stellenbosch in South Africa and M.M. and Ph.D. from the University of Texas at Austin.Appointment Date: July 1, 2021

Edward MiaoProfessor of ImmunologyEdward Miao is professor of immunology and molecular genetics and microbiology in the Basic Science Division of the School of Medicine. He studies how immune cells detect intracellular infection, and how programmed cell death removes the infected cells from the body, studying a range of bacterial pathogens including Salmonella, Listeria, and rare environmental pathogens. Miaos research has been featured in a number of notable academic journals including Science, Nature Immunology, Immunity, and Cell Host and Microbe. His research is largely funded by the National Institutes of Health. Miao joined Duke in 2020, having previously held a faculty position with the University of North Carolina at Chapel Hill. He earned his M.D./Ph.D. from the University of Washington.Appointment Date: March 1, 2021

Natalia MirovitskayaProfessor of the Practice of Public PolicyNatalia Mirovitskayasprofessional focus is on political economy of development and peacebuilding. Following the completion of her Ph.D. from the Russian Academy of Sciences (Economics), Mirovitskaya has led and participated in numerous projects on the design, implementation and effectiveness of international resource regimes, environmental security, sustainable development and conflict prevention. Mirovitskayas experience has displayed an interdisciplinary approach linking theoretical advances with practical policy advice. She has co-authored Development Strategies and Inter-Group Violence,and co-edited Economic Development Strategies and the Evolution of Violence in Latin America, Development Strategies, Identities, and Conflict in Asia, and The Economic Roots of Conflict and Cooperation in Africa. Mirovitskayas most recent project is on Development for the New Arctic: Visions, Strategies, Challenges at the Subnational and Local Level. She is also co-editor of the Palgrave Macmillan series Politics, Economics and Inclusive Development. At Duke, Dr. Mirovitskaya teaches classes in Policy Analysis for Development, Policy Design, Research Methods, and Conflict-Sensitive Development. She has directed masters projects for fellows from over sixty countries, worked on executive education training of senior government officials and civil society leaders, and provided consultancies on security and sustainable development issues. She is a recipient of many research and teaching awards including theU.S. National Research Council Certificate of Appreciation for Outstanding Service and theRichard Stubbing Graduate Teaching.Appointment Date: July 1, 2021

Christopher MonroeGihuly Family Presidential Distinguished Professor of Electrical and Computer Engineering and PhysicsChristopher Monroe is the Gilhuly Family Presidential Distinguished Professor of Electrical and Computer Engineering in the Pratt School of Engineering and Physics in the Trinity College of Arts & Sciences. He is also the director of the Duke Quantum Center. Monroe is an experimental atomic and quantum physicist and engineer, with interests in fundamental quantum phenomena, quantum information science, and quantum computer design and fabrication. His research group pioneered most aspects of ion trap quantum computers, making the first steps toward a scalable, reconfigurable, and modular quantum computer system. Monroe is also co-founder and Chief Scientist at IonQ, a company near Washington, DC that builds quantum computers based on trapped atomic ions. He is an architect of the U.S. National Quantum Initiative and a member of the National Academy of Sciences.Appointment Date: January 1, 2021

Joseph NadeauProfessor of the Practice of Civil and Environmental EngineeringDr. Joseph C. Nadeau is a professor of the practice of civil and environmental engineering in the Pratt School of Engineering. He joined the Duke faculty in 1997. For six years, he was the faculty-in-residence in Few Quad. He currently serves as director of undergraduate studies, ABET Coordinator and ASCE faculty advisor. He teaches courses in mechanics and structural design. His teaching has been recognized with multiple teaching awards from departmental, school and national sources. He received his doctorate from the University of California at Berkeley and his masters and bachelors degrees from MIT and Lehigh University, respectively. His research interests are in the areas of structural design and composite materials. He is a registered professional engineer.Appointment Date: January 1, 2021

Kristen NeuschelProfessor of HistoryKristen Neuschel is professor of history in the Trinity College of Arts & Sciences. She is also co-director of the Language, Arts and Media Program. Her research concentrates on late medieval and early modern France and Europe with a current focus on war and culture in northern Europe between 1400 and 1600 A.D. She is the author of two monographs,Living by the Sword (2020) and Word of Honor (1989),and co-author to several editions of a textbook,Western Civilization: Beyond Boundaries (2013). Neuschel teaches courses in the history of war, of gender relations, and in the writing and (at the graduate level) the teaching of History. She earned her B.A. from Denison University and M.A. and Ph.D. from Brown University.Appointment Date: July 1, 2021

James NolenProfessor of MathematicsJames Nolen is professor of mathematics in the Trinity College of Arts & Sciences. He studies partial differential equations and probability, which have been used to model many phenomena in the natural sciences and engineering with special interest in differential equations modeling random phenomena and whether one can describe the statistical properties of solutions to these equations. Nolens current research interests include reaction diffusion equations, homogenization of PDEs, stochastic dynamics and interacting particle systems. His research is funded by the National Science Foundation and was granted the CAREER award for Research and training in stochastic dynamics. He earned his B.S. from Davidson College and Ph.D. from the University of Texas at Austin.Appointment Date: July 1, 2021

David PageProfessor of Biostatistics & BioinformaticsDavid Page is professor and chair of the Department of Biostatistics and Bioinformatics in the Basic Science Division of the School of Medicine. He develops algorithms for machine learning and causal discovery, as well as applying them to biomedical data, especially de-identified electronic health records and high-throughput genetic and other molecular data. His research is funded by the National Institutes of Health and the National Science Foundation. Page earned his Ph.D. in Computer Science from the University of Illinois at Urbana-Champaign.He became involved in biomedical applications while a post-doc at Oxford University, and he was formerly a Kellett and Vilas Distinguished Achievement Professor at the University of Wisconsin-Madison before moving to Duke.Appointment Date: May 1, 2021

Henry PickfordProfessor of German StudiesHenry Pickford is professor of German studies in the Trinity College of Arts & Sciences. His research interests focus on modern philosophy and literature in German and Russian, with emphasis on the German philosophical tradition from Kant to critical theory. He is the author of The Sense of Semblance: Philosophical Analyses of Holocaust Art, Thinking with Tolstoy and Wittgenstein: Emotion, Expression and Art (also forthcoming in Russian translation), co-author of In Defense of Intuitions: A New Rationalist Manifesto, co-editor of Der aufrechte Gang im windschiefen Kapitalismus: Modelle kritischen Denkens, editor and translator of Theodor W. Adornos Critical Models: Interventions and Catchwords and Selected Early Poems of Lev Loseff and author of over twenty-five articles and book chapters. He is currently co-authoring the book Adorno: A Critical Life and co-editing the Oxford Handbook to Adorno. Pickford has a secondary appointment in Duke's Philosophy department. He earned his D.Phil. in Comparative Literature from Yale University and a M.A. in Philosophy from University of Pittsburgh.Appointment Date: January 1, 2021

Shitong QiaoProfessor of LawShitong Qiao is professor of law and the Ken Young-Gak Yun and Jinah Park Yun Research Scholar at Duke Law School. He was a tenured professor at the University of Hong Kong, a Law and Public Affairs (LAPA) fellow at Princeton University, and the inaugural Jerome A. Cohen Visiting Professor of Law at NYU. He also taught law in Shenzhen and Shanghai. Professor Qiao is an expert on property and urban law with a focus on comparative law and China. His first monograph, Chinese Small Property: The Co-Evolution of Law and Social Norms, won multiple prizes from Yale, Tsinghua and Hong Kong. His works in progress include a book under contract with Cambridge titled The Authoritarian Commons: Neighborhood Democratization in Urban China and the first-ever empirical investigation of the Supreme Peoples Court of China. He has advised the Shenzhen city government and the Ontario Securities Commission on Chinese land law and policies.Appointment Date: August 16, 2021

Sarah Bloom RaskinProfessor of the Practice of LawSarah Bloom Raskin, the former deputy secretary of the U.S. Department of the Treasury, was named the Colin W. Brown Distinguished Professor of the Practice of Law in 2021. A distinguished fellow in the Law SchoolsGlobal Financial Markets Center, she will become the centers faculty directorin January 2022. She is also a senior fellow in the Duke Center on Risk.From 2014 to 2017, Raskin was the second-in-command at the Treasury Department, where she was known for her pursuit of innovative solutions to enhance Americans shared prosperity, the resilience of the countrys critical financial infrastructure, and the defense of consumer safeguards in the financial marketplace. Earlier, Raskin was a governor of the Federal Reserve Board and a member of the Federal Open Market Committee. She also served as commissioner of financial regulation for the State of Maryland from 2007 to 2010. As a Rubenstein Fellow at Duke, Raskin collaborated with faculty across the university to improve understanding of markets and regulation. She led an agenda focused on shaping a new relationship between regulation and resilience in financial markets and deepening understanding of the management of systemic risks from diverse sources such as financial instruments, cyber breaches, and climate events. She also mentored and advised undergraduate and graduate students on careers in the public sector, guest-lectured in courses, participated in public events, and led collaborative research projects. Raskin, a graduate of Harvard Law School, has throughout her career worked across public and private sectors in both legal and regulatory capacities. Her private sector experience includes having served as managing director at the Promontory Financial Group, general counsel of the WorldWide Retail Exchange, and at the law firms of Arnold and Porter and Mayer Brown. Earlier in her career she served as banking counsel for the U.S. Senate Committee on Banking, Housing, and Urban Affairs.Appointment Date: August 1, 2021

Michael ReiterJames B. Duke Distinguished Professor of Computer Science and Electrical & Computer EngineeringMichael Reiter is James B. Duke Distinguished Professor of Computer Science in the Trinity College of Arts & Sciences and electrical and computer engineering in the Pratt School of Engineering. His research interests include all areas of computer and communications security, fault-tolerant distributed computing and applied cryptography. His previous positions included Director of Secure Systems Research at Bell Labs, professor of electrical and computer engineering and computer science at Carnegie Mellon University, and distinguished professor of computer science at the University of North Carolina at Chapel Hill. He earned his Ph.D. from Cornell University.Appointment Date: January 1, 2021

Ronald RittgersProfessor of the History of Christianity, Duke Divinity Chair in Lutheran StudiesDr. Rittgers research interests include the religious, intellectual, social and cultural history of medieval and early modern/Reformation Europe, focusing especially on the history of theology and devotion. Rittgers has served as the President of the American Society of Church History. His many publications include articles and book chapters in addition to books:The Reformation of the Keys:Confession, Conscience, and Authority in Sixteenth-Century Germany;The Reformation of Suffering: Pastoral Theology and Lay Piety in Late Medieval and Early Modern Germany; The Reformation Commentary on Scripture: Hebrews and James; a co-edited volume,Protestants and Mysticism in Reformation Europe; andA Widowers Lament: The Pious Meditations of Johann Christoph Oelhafen. His next research projects will examine the intersection of consolation and self-understanding in the Age of Reform and the history of disenchantment in the Reformation and beyond. He additionally intends to work on essays that examine lament and love of God, respectively, in the theology of Martin Luther.Appointment Date: June 1, 2021

Jennifer SiegelBruce R. Kuniholm Distinguished Professor of History and Public PolicyJennifer Siegel Bruce R. Kuniholm Distinguished Professor of History in the Trinity College of Arts & Sciences and Public Policy in the Sanford School. She is an historian whose work focuses on the international and transnational nature of foreign relations and international security in the nineteenth and twentieth centuries, and the ways in which those relations were driven by political, cultural, social, and economic forces. Her research has centered in the areas of international diplomacy, finance, the origins of wars, the nature of alliances, and modern intelligence, with a particular focus to date on relations between and among the Entente powers of Britain, Russia and France on the European continent and in the imperial periphery.Her most recent book,For Peace and Money: French and British Finance in the Service of Tsars and Commissars, examines the globalized interconnectivity of finance and foreign policy in the context of British and French private and government bank loans to Russia in the late imperial period up to the Genoa Conference of 1922.Appointment Date: July 1, 2021

J. Warren SmithProfessor of Historical TheologyJ. Warren Smith is professor of historical theology in the Divinity School. His interest in the history of theology is broadly conceived from the apostles to the present, but his primary interest is the theology of the first six centuries of the Church. He is the author of Passion and Paradise: Human and Divine Emotion in the Thought of Gregory of Nyssa, Christian Grace and Pagan Virtue: The Theological Foundation of Ambrose's Ethics, and Ambrose, Augustine, and the Pursuit of Greatness. He is currently working on a volume for Eerdmans Publishing tracing the development of theology from the Apostolic era with Ignatius of Antioch to the high-water mark of Byzantine thought with Maximos the Confessor, entitledEarly Christian Theology: A History.Beyond that Smith is turning to a project, tentatively entitledPlato and Christ: Platonism in Early Christian Theology,thatwill examine the significance of the tradition called "Christian Platonism" for Christianity in a post-modern age. He is also a United Methodist minister in the North Carolina Annual Conference. Smith earned his Ph.D. from Yale University.Appointment Date: January 1, 2021

Kevin WhiteProfessor of the Practice of Business AdministrationKevin M. White is professor of the practice of business administration in theFuqua School of Business. He is also vice president and director of athletics, emeritus. White earned his Ph.D. in education from Southern Illinois University in 1983 and currently teaches a sports business course as part of Fuquas Daytime MBA program. White guided Duke's Athletic Department from 2008-21 and spearheaded the implementation of the strategic plan approved by Dukes Board of Trustees in April 2008. He led Duke Athletics to unprecedented success in competition, reshaped the organization into a more efficient department and implemented significant diversity and inclusion efforts for the entire department. White has mentored more than 30 current or former directors of athletics and conference commissioners. Prior to his arrival in Durham, White served as athletic director at the University of Notre Dame, Arizona State University, Tulane University, the University of Maine and Loras College in Iowa. He graduated from the Harvard Institute of Educational Management in 1985. He is a member of the United States Olympic andParalympicCommittee and former chairman of the NCAA Mens Basketball Selection Committee.Appointment Date: September 1, 2021

Justin WrightProfessor of BiologyJustin Wright is professor of biology in the Trinity College of Arts & Sciences with a secondary appointment in the Nicholas School of the Environment. His research focuses on understanding the causes and consequences of patterns of biological diversity across the planet. His research has received funding from the National Science Foundation, National Aeronautics and Space Administration, National Geographic Society, U.S. Army Research, Development & Engineering Command and the Oak Ridge National Laboratory. Wright joined Duke faculty in 2003. He earned his B.A. from Williams College and Ph.D. from Cornell University.Appointment Date: July 1, 2021

By Maggie Elliott

See more here:
Duke Faculty Promoted or Appointed to the Rank of Full Professor - Duke Today

Posted in Michigan Stem Cells | Comments Off on Duke Faculty Promoted or Appointed to the Rank of Full Professor – Duke Today

Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent … – KULR-TV

Posted: November 8, 2021 at 2:32 am

Updates from OTL-201 Clinical Proof-of-Concept Study in MPS-IIIA and OTL-204 Preclinical Study for GRN-FTD at ESGCT Showcase Potential for HSC Gene Therapy in Multiple Neurodegenerative Disorders

Launch Activities for Libmeldy Across Key European Countries, including Reimbursement Discussions, Progressing in Anticipation of Treating Commercial Patients

Frank Thomas, President and Chief Operating Officer, to Step Down Following Transition in 2022; Search for a Chief Financial Officer Initiated

Cash and Investments of Approximately $254M Provide Runway into First Half 2023

BOSTONandLONDON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today reported financial results for the quarter ended September 30, 2021, as well as recent business updates and upcoming milestones.

This quarter, we are pleased by the progress demonstrated by our investigational neurometabolic HSC gene therapy programs with promising preclinical and clinical updates at ESGCT, said Bobby Gaspar, M.D., Ph.D., chief executive officer of Orchard. With follow-up in OTL-201 for MPS-IIIA patients now ranging between 6 and 12 months, biomarker data remain highly encouraging, showing supraphysiological enzyme activity and corresponding substrate reductions in the CSF and urine. The launch strategy for Libmeldy is also advancing in Europe with momentum building on reimbursement discussions and patient finding activities.

Recent Presentations and Business Updates

Data presentations at ESGCT

Clinical and pre-clinical data from across the companys investigational hematopoietic stem cell (HSC) gene therapy portfolio were featured in two oral and seven poster presentations at the European Society of Gene & Cell Therapy Congress (ESGCT) on October 19-22. Highlights from key presentations are summarized below:

OTL-201 for Mucopolysaccharidosis type IIIA (MPS-IIIA): A poster presentation featured supportive biomarker data from the first four patients with evaluable results, with duration of follow-up ranging from 6 to 12 months. The treatment has been generally well-tolerated in all enrolled patients (n=5) with no treatment-related serious adverse events (SAEs). Supraphysiological N-sulphoglucosamine sulphohydrolase ( SGSH) enzyme activity above the normal range was seen in leukocytes and plasma within one to three months in all evaluable patients (n=4).A greater than 90% reduction in urinary glycosaminoglycans (GAGs) was seen within three months in all evaluable patients (n=4).SGSH activity in the cerebrospinal fluid (CSF) increased from undetectable at baseline to within or above the normal range by six months in all patients with available data (n=3).CSF GAGs decreased from baseline in patients with available data (n=3).OTL-204 for Progranulin-mutated Frontotemporal Dementia (GRN-FTD): Preliminary in vivo data from the preclinical proof-of-concept study showed that murine GRN -/- HSPCs, transduced with an LV expressing progranulin under the control of a novel promoter, are able to engraft and repopulate the brain myeloid compartment of FTD mice and to locally deliver the GRN enzyme.

R&D Investor Event Summary

In September, Orchard hosted an R&D investor event highlighting its discovery and research engine in HSC gene therapy, including an update on the OTL-104 program in development for NOD2 Crohns disease (NOD2-CD) and potential new applications in HSC-generated antigen-specific regulatory T-cells (Tregs) and HSC-vectorization of monoclonal antibodies (mAbs).

The discussion also covered the differentiated profile of Orchards HSC gene therapy approach, which has exhibited favorable safety, long-term durability and broad treatment applicability.

In particular, Orchards lentiviral vector-based HSC gene therapy programs have shown no indication of insertional oncogenesis and no evidence of clonal dominance due to integration into oncogenes. Importantly, the promoters and regulatory elements of Orchard vectors are derived from human (not viral) sequences and are specifically designed to have limited enhancer activity on neighboring genes thereby mitigating the potential for safety concerns.In addition, because of the fundamental biological differences between the HSC and adeno-associated virus (AAV) gene therapy approaches, Orchards programs have not, to date, seen the safety and durability concerns experienced by the AAV gene therapy field.

Libmeldy (atidarsagene autotemcel) launch in Europe

Orchard is providing an update on the following key launch activities for Libmeldy in Europe:

Discussions with health authorities and payors are underway across Europe in key markets including Germany, the UK, France and Italy.Qualification of treatment centers is progressing with The University of Tbingen in Germany ready to treat commercial patients and other centers in the final stages of qualification and treatment readiness.Disease awareness and patient identification activities continue and have supported patient referrals in major European centers. Orchards partnerships in the Middle East and Turkey allow for opportunities to treat eligible patients from these territories at qualified European centers.Orchard is providing sponsorship for an ongoing newborn screening pilot in Germany and is working with laboratories to implement pilots in Italy, the UK, France and Spain.

Executive organizational update

The company also announced that Frank Thomas will step down from his role as president and chief operating officer, following a transition in 2022. A search for a chief financial officer is underway. Mr. Thomas other responsibilities will be assumed by existing members of the leadership team in commercial and corporate affairs. Orchard recently strengthened the executive team with the appointments of Nicoletta Loggia as chief technical officer and Fulvio Mavilio as chief scientific officer and the promotion of Leslie Meltzer to chief medical officer.

I want to extend my gratitude to Frank Thomas for his immense contributions to Orchard, said Gaspar. During his tenure, Frank oversaw the transition of the organization to a publicly traded company and has managed operations with a focus on cross-company innovation, including his role as a key architect in creating and executing the focused business plan we rolled out in 2020. Along with the entire board of directors and leadership team, I appreciate Franks commitment to facilitate a smooth transition during this time.

Gaspar continued, Our search is focused on a CFO to lead the broad strategic planning efforts necessary to capitalize on the full potential of our hematopoietic stem cell gene therapy platform. We have a strong team in place to aid Orchards success in this next phase of growth and are well capitalized through the anticipated completion of several value-creating milestones.

Upcoming Milestones

In June 2021, Orchard announced several portfolio updates following recent regulatory interactions for the companys investigational programs in metachromatic leukodystrophy (MLD), Mucopolysaccharidosis type I Hurler syndrome (MPS-IH) and Wiskott-Aldrich syndrome (WAS).

OTL-200 for MLD in the U.S: Based on feedback received from the U.S. Food and Drug Administration (FDA), the company is preparing for a Biologics License Application (BLA) filing for OTL-200 in pre-symptomatic, early-onset MLD in late 2022 or early 2023, using data from existing OTL-200 patients. This approach and timeline are subject to the successful completion of activities remaining in advance of an expected pre-BLA meeting with FDA, including future CMC regulatory interactions and demonstration of the natural history data as a representative comparator for the treated population.OTL-203 for MPS-IH: Orchard is incorporating feedback from FDA and the European Medicines Agency (EMA) into a revised global registrational study protocol, with study initiation expected to occur in 2022.OTL-201 for MPS-IIIA: Additional interim data from this proof-of-concept study are expected to be presented at medical meetings in 2022, including early clinical outcomes of cognitive function.OTL-103 for WAS: The company expects a MAA submission with EMA for OTL-103 in WAS in 2022, subject to the completion of work remaining on potency assay validation and further dialogue with EMA. The company will provide updated guidance for a BLA submission in the U.S. following additional FDA regulatory interactions.

Third Quarter 2021 Financial Results

Revenue from product sales of Strimvelis were $0.7 million for the third quarter of 2021 compared to $2.0 million in the same period in 2020, and cost of product sales were $0.2 million for the third quarter of 2021 compared to $0.7 million in the same period in 2020. Collaboration revenue was $0.5 million for the third quarter of 2021, resulting from the collaboration with Pharming Group N.V. entered into in July 2021. This revenue represents expected reimbursements for preclinical studies and a portion of the $17.5 million upfront consideration received by Orchard under the collaboration, which will be amortized over the expected duration of the agreement.

Research and development (R&D) expenses were $20.8 million for the third quarter of 2021, compared to $14.7 million in the same period in 2020. The increase was primarily due to higher manufacturing and process development costs for the companys neurometabolic programs and lower R&D tax credits as compared to the same period in 2020. R&D expenses include the costs of clinical trials and preclinical work on the companys portfolio of investigational gene therapies, as well as costs related to regulatory, manufacturing, license fees and development milestone payments under the companys agreements with third parties, and personnel costs to support these activities.

Selling, general and administrative (SG&A) expenses were $13.0 million for the third quarter of 2021, compared to $13.0 million in the same period in 2020. SG&A expenses are expected to increase in future periods as the company builds out its commercial infrastructure globally to support additional product launches following regulatory approvals.

Net loss was $36.4 million for the third quarter of 2021, compared to $20.3 million in the same period in 2020. The increase in net loss as compared to the prior year was primarily due to higher R&D expenses as well as the impact of foreign currency transaction gains and losses. The company had approximately 125.5 million ordinary shares outstanding as of September 30, 2021.

Cash, cash equivalents and investments as of September 30, 2021, were $254.1 million compared to $191.9 million as of December 31, 2020. The increase was primarily driven by net proceeds of $143.6 million from the February 2021 private placement and $17.5 million in upfront payments from the July 2021 collaboration with Pharming Group N.V., offset by cash used for operating activities and capital expenditures. The company expects that its cash, cash equivalents and investments as of September 30, 2021 will support its currently anticipated operating expenses and capital expenditure requirements into the first half of 2023. This cash runway excludes an additional $67 million that could become available under the companys credit facility and any non-dilutive capital received from potential future partnerships or priority review vouchers granted by the FDA following future U.S. approvals.

About Libmeldy / OTL-200 Libmeldy (atidarsagene autotemcel), also known as OTL-200, has been approved by the European Commission for the treatment of MLD in eligible early-onset patients characterized by biallelic mutations in the ARSA gene leading to a reduction of the ARSA enzymatic activity in children with i) late infantile or early juvenile forms, without clinical manifestations of the disease, or ii) the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline. Libmeldy is the first therapy approved for eligible patients with early-onset MLD. The most common adverse reaction attributed to treatment with Libmeldy was the occurrence of anti-ARSA antibodies. In addition to the risks associated with the gene therapy, treatment with Libmeldy is preceded by other medical interventions, namely bone marrow harvest or peripheral blood mobilization and apheresis, followed by myeloablative conditioning, which carry their own risks. During the clinical studies, the safety profiles of these interventions were consistent with their known safety and tolerability. For more information about Libmeldy, please see the Summary of Product Characteristics (SmPC) available on the EMA website. Libmeldy is approved in the European Union, UK, Iceland, Liechtenstein and Norway. OTL-200 is an investigational therapy in the US.

Libmeldy was developed in partnership with the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy. About Orchard

At Orchard Therapeutics, our vision is to end the devastation caused by genetic and other severe diseases. We aim to do this by discovering, developing and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patients own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease in a single treatment.

In 2018, the company acquired GSKs rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Today, Orchard has a deep pipeline spanning pre-clinical, clinical and commercial stage HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.

Orchard has its global headquarters inLondonandU.S. headquarters inBoston. For more information, please visit http://www.orchard-tx.com, and follow us on Twitter and LinkedIn.

Availability of Other Information About Orchard

Investors and others should note that Orchard communicates with its investors and the public using the company website ( http://www.orchard-tx.com ), the investor relations website ( ir.orchard-tx.com ), and on social media ( Twitter and LinkedIn ), including but not limited to investor presentations and investor fact sheets,U.S. Securities and Exchange Commissionfilings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchards investor relations website and may include additional social media channels. The contents of Orchards website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward-Looking Statements

This press release contains certain forward-looking statements about Orchards strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include express or implied statements relating to, among other things, Orchards business strategy and goals, including its plans and expectations for the commercialization of Libmeldy, the therapeutic potential of Libmeldy (OTL-200) and Orchards product candidates, including the product candidates referred to in this release, Orchards expectations regarding its ongoing preclinical and clinical trials, including the timing of enrollment for clinical trials and release of additional preclinical and clinical data, the likelihood that data from clinical trials will be positive and support further clinical development and regulatory approval of Orchard's product candidates, and Orchards financial condition and cash runway into the first half of 2023. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchards control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation: the risk that prior results, such as signals of safety, activity or durability of effect, observed from clinical trials of Libmeldy will not continue or be repeated in our ongoing or planned clinical trials of Libmeldy, will be insufficient to support regulatory submissions or marketing approval in the US or to maintain marketing approval in the EU, or that long-term adverse safety findings may be discovered; the risk that any one or more of Orchards product candidates, including the product candidates referred to in this release, will not be approved, successfully developed or commercialized; the risk of cessation or delay of any of Orchards ongoing or planned clinical trials; the risk that Orchard may not successfully recruit or enroll a sufficient number of patients for its clinical trials; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchards product candidates; the delay of any of Orchards regulatory submissions; the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchards product candidates or the receipt of restricted marketing approvals; the inability or risk of delays in Orchards ability to commercialize its product candidates, if approved, or Libmeldy, including the risk that Orchard may not secure adequate pricing or reimbursement to support continued development or commercialization of Libmeldy; the risk that the market opportunity for Libmeldy, or any of Orchards product candidates, may be lower than estimated; and the severity of the impact of the COVID-19 pandemic on Orchards business, including on clinical development, its supply chain and commercial programs. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchards quarterly report on Form 10-Q for the quarter endedSeptember 30, 2021, as filed with theU.S. Securities and Exchange Commission(SEC), as well as subsequent filings and reports filed with theSEC. The forward-looking statements contained in this press release reflect Orchards views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contacts

Investors Renee Leck Director, Investor Relations +1 862-242-0764 Renee.Leck@orchard-tx.com

Media Benjamin Navon Director, Corporate Communications +1 857-248-9454 Benjamin.Navon@orchard-tx.com

Read the original:
Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent ... - KULR-TV

Posted in Stem Cell Treatments | Comments Off on Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent … – KULR-TV

Medicines Wellness Conundrum – The New Yorker

Posted: November 8, 2021 at 2:28 am

Michelle didnt yank Tobys socks off from the toes. She rolled them down from the calf, using both hands, pausing to cradle each newly bare foot. She gently ran her hands up and down Tobys exposed shins. She touched one of Tobys wrists to feel her pulse, and pressed the tips of her thumbs between Tobys eyes and at her ankles for a few seconds at a time. Sometimes, she held a hand an inch or so above Tobys skin, then moved it through the air, as though dusting an invisible shelf.

A soft cap warmed Tobys nearly hairless head; the waxen pallor of chemotherapy hung on her face. She was in the middle of a yearlong course of treatment for early-stage breast cancer, at New York-Presbyterian/Columbia Hospital, in Manhattan. A few months earlier, Toby, who lives in New Jersey, had undergone a double mastectomy and begun chemotherapy. When the chemo made her nauseated, and the nausea medication only made her feel worse, she began meeting weekly with Michelle Bombacie, who manages the Integrative Therapies Program at Columbia University Irving Medical Center, for a mixture of acupuncture, acupressure, light-touch massage, and Reiki.

Wellness is an umbrella term. It can be used to cover forms of traditional Chinese medicine, such as acupressure and acupuncture; aspects of the Indian tradition Ayurveda; and more recent inventions like Reiki, which involves pressure-free caressing and non-touch hand movements. It can also encompass nutritional counselling, herbal supplements, exercise, homeopathy, massage, reflexology, yoga, touch therapy, art therapy, music therapy, aromatherapy, light therapy, and more. The wellness movement is one of the defining characteristics of health care in this era, Timothy Caulfield, a University of Alberta professor focussed on health and science policy, told me. By some estimates, the wellness industry, loosely defined, is worth over four trillion dollars.

Wellness is often presented as an alternative to the modern medical system, and is pursued in spas or other dedicated spaces. But, in recent years, hospitals have begun embracing it, too. By one estimate, around four hundred American hospitals and cancer centers now host a wellness facility of some kind; most offer services aimed at stress reduction and relaxation, but many also promise to help patients improve their energy levels, strengthen their immune systems, and reduce chemotherapy-induced fatigue and nausea. A few provide fringe services, such as apitherapy (which uses bee products, such as honey or venom), or promise to adjust patients life force. Cancer patients are particularly drawn to whats known as complementary care: up to ninety per cent use some service that falls under the aegis of wellness. At some of the countrys top health-care institutions, patients can receive chemotherapy in one wing of the hospital and, in another, avail themselves of aromatherapy, light-touch massage, and Reikiinterventions that are not supported by large, modern studies and that are rarely covered by insurance.

The commingling of medicine and wellness has been alarming for some physicians. Weve become witch doctors, Steven Novella, a neurologist at the Yale School of Medicine, told the medical Web site STAT, in 2017. Patients at such centers are being snookered, Novella argued, and hospitals commit an ethical error in offering services in wellness centers that they would eschew on their medical floors. (Novella is the founder of Science-Based Medicine, a Web site dedicated to debunking alternative therapies.) Many physicians find Reiki particularly unnerving: practitioners of the technique, which was invented in Japan in the early twentieth century, move their hands on or over the body, ostensibly to shift the flow of energy within it. In 2014, in an article in Slate, the science journalist Brian Palmer reviewed the literature on Reiki and found no evidence that it workedit was, he wrote, beneath the dignity of a great cancer center to offer it.

On the other hand, some doctors support the provision of wellness interventionseven those not backed up by rigorous studiesas long as they do no harm and dont replace medical care. And many patients feel that such interventions help them. After Toby started seeing Michelle Bombacie, her nausea disappeared, and she became energetic enough to care for two puppies. I know something changed within me, she told me. Although Toby didnt have strong views about how Reiki works, she described the experience with Bombacie as critical to the success of her treatment. It gave me the tools to work on my mental health and spiritual health, and to shift my focus from being out of control and kind of helpless to having more trust in myself and my doctors, she said. Kim Turk, the lead massage therapist at Duke Integrative Medicine, told me that she considers Reiki practitioners to be facilitators who support peoples own healing.

Patient satisfaction matters to hospitalsMedicare penalizes them for low satisfaction ratings. Massages and yoga may make patients happier and keep them coming back. Hospitals are banking on the fact that treating you in a more humane way will make you want to stay as a customer, Thomas DAunno, a New York University professor whose focus includes health-care management, said. And yet medicine, if it is to function, depends on trust. Hospitals are supposed to be bastions of evidence-based care; wellness treatments dont meet that standard. Can the best of wellness be brought into the hospital without compromising the integrity on which health care depends?

The term wellness, as we use it today, dates roughly to 1961, when Halbert L. Dunn, an eminent biostatistician and former head of the National Office of Vital Statistics, published the book High-Level Wellness. Dunn took his cue from the constitution of the World Health Organization, ratified in 1948, which redefined health as a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity. Wellness, he wrote, was about functioning better over timehaving an ever-expanding tomorrow. This inspirational idea found a broad audience. In the nineteen-seventies, so-called wellness centers began offering fee-for-service therapies; in the following decades, corporate wellness programs subsidized gym memberships and meditation classes.

The new concept dovetailed with an ongoing medical story. American doctoring in the nineteenth century, as the medical historian Norman Gevitz has written, was characterized by poorly trained practitioners employing harsh therapies to combat disease entities they understood insufficiently. As a result, osteopathy, homeopathy, and chiropractic techniques attracted educated, conventionally trained physicians who were frustrated with treatments that didnt seem to work. Mainstream doctors readily embraced what wed now call alternative therapies until 1910, when the Carnegie Foundation asked Abraham Flexner, an education reformer from Louisville, Kentucky, to report on the state of medical schools in the U.S. and Canada. Flexner evaluated a hundred and fifty-five medical schools according to the standards of the German medical system, which emphasized rigorous research; in his report, he warned of rampant charlatanism and quackery, and called for an end to treatments that werent evidence-based. Many medical schools closed soon after the report was published.

The Flexner Report ushered in the modern era of American medicine, in which interventions are based on reliable evidence. But Flexners disregard for bedside manner and other intangibles had an unexpected consequence. The professions infatuation with the hyper-rational world of German medicine created an excellence in science that was not balanced by a comparable excellence in clinical caring, Thomas Duffy, a professor at the Yale School of Medicine, wrote, in a centennial history of the report. Physicians, Duffy argued, began to distance themselves from patients. It fell to nurses to provide the empathy that doctoring no longer facilitated, by comforting, massaging, listening, and expressing compassion.

Advances in technology further chilled the clinic. Medicine had long been synonymous with the laying on of handswith diagnosis by feel and the use of healing touch. Patients, the medical historian Jacalyn Duffin told me, were essentially the authorities on whether they were sick; it was up to physicians to isolate the cause. The invention of the stethoscope, in 1816, shifted the balance. You werent sick unless the doctor found something, Duffin said. By the end of the twentieth century, diagnostic devicesX-ray machines, MRI scanners, and ultrasoundshad made diagnosis increasingly objective while allowing doctors to conduct mostly touch-free exams. Abraham Verghese, an infectious-disease physician at the Stanford University School of Medicine, has written that, for doctors today, the patient in the bed can seem almost as an icon for the real patient whos in the computer.

These days, moreover, medical practice is focussed on efficiency. In surveys, most doctors say that they spend between nine and twenty-four minutes with each patient per visit. (This may be an overestimate.) One study has found that physicians listen to their patients for an average of eleven seconds before interrupting. There is a gap between what we want from health care and what we get. Wellness stands ready to fill it.

Lila Margulies, a high-school friend of mine, was diagnosed with lung cancer, in March, 2017. Forty-three years old and a nonsmoker, she underwent surgery, chemotherapy, and radiation before the cancer spread to her bones. She had already been interested in wellnesstaking herbal supplements, visiting an acupuncturistand the cancer deepened her interest in alternative approaches. Alongside her treatment, Lila adopted a diet that she believed would stop her cancer from growing, increased her supplement intake, and began working with an energy healer. Her friends contributed to a GoFundMe campaign so that she could afford the expensive healing sessions.

Lila was open with her oncologist about her extra-medical pursuits. She met regularly with her energy healer at his home, in Mahopac, New York, for sessions that combined conversationhe spoke with her about her fear of leaving her young children behindwith a cross-cultural mix of touch therapies. All of it came back to energy and how energy moves in the body and between people, Lila told me. Her cancer was stable for several years; last fall, she learned that it had begun spreading again. She continues to feel that her sessions with her healer were beneficial. It was so tangible, she said. It made a huge difference.

Research has explained some of the physical mechanisms that underlie our enjoyment of light touch. In the late nineteen-thirties, a Swedish neurophysiologist named Yngve Zotterman discovered nerve fibres in cats that respond to slow, gentle touch. In the nineteen-nineties, another neurophysiologist from Sweden, ke Vallbo, working with other researchers, found that the same fibres existed in people. The nerves, known as C-tactile afferents, or CT fibres, prompt not only a physical sensation but also pleasant emotions. Gentle strokingat one to ten centimetres per second, with a hand or a body-temperature objectreleases opiates, along with other chemicals that make us feel good. These relaxing effects originate in the manipulation of the skin. Theres a specific receptor and a specific pathway, Frauke Musial, a professor at the government-funded National Research Center in Complementary and Alternative Medicine, at the Arctic University of Norway, told me. Without touch, we never experience the feelings that touch causes.

Go here to read the rest:
Medicines Wellness Conundrum - The New Yorker

Posted in Integrative Medicine | Comments Off on Medicines Wellness Conundrum – The New Yorker

Forum Health Welcomes Tara Scott, MD and First Location in Ohio – PRNewswire

Posted: November 8, 2021 at 2:28 am

FLINT, Mich., Nov. 2, 2021 /PRNewswire/ -- Forum Health, LLC, the first nationwide network of integrative and functional medicine providers, has acquired Revitalize Medical Group, a functional medicine practice founded by Tara Scott, MD located in Fairlawn, Ohio.

Revitalize Medical Group focuses on women's health, treating hormonal imbalances, stress, thyroid issues, infertility, nutrition and more.

"We are proud to announce that Revitalize is our first Forum Health location in the state of Ohio," said Adam Puttkammer, president of Forum Health. "Dr. Scott is a leader in the field of women's health and specifically natural approaches to treating hormones. She brings a wealth of knowledge to our network."

Dr. Scott began as an OB/GYN and is nationally recognized for her work in hormone and wellness-related issues. She incorporates integrative medicine and evidence-based therapies to treat women's hormone-related and chronic health concerns.

"I am excited for our Revitalize team to join the Forum Health network," said Dr. Scott. "We'll be able to leverage leading integrative and functional medicine providers, as well as rely on a team of professionals to support the non-clinical side of our practice."

An expert speaker and educator, she's taught doctors her approach for the past 10 years across five continents. She's been featured in podcasts, The List, Authority Magazine, Thrive Global and a 2021 TEDx talk.

"Dr. Scott's dedication to education on integrative and evidence-based therapies aligns with Forum Health's philosophy," said Phil Hagerman, CEO of Forum Health. "Her expertise in anti-aging therapies and regenerative medicine will greatly contribute to our network."

Dr. Scott is certified in anti-aging, regenerative and functional medicine; board certified in Integrative Medicine, a North American Menopause Society Certified Menopause Practitioner, clinical assistant professor of OB/GYN at Northeast Ohio Medical University and current Medical Director for Integrative Medicine at Summa Health in Akron, OH.

For more information on Forum Health, visit http://www.forumhealth.com.

About Forum Health, LLCForum Health, LLC is a nationwide provider of personalized healthcare. Steeped in the powerful principles of functional and integrative medicine, Forum Health providers take a root-cause approach to care. They listen and dig deep exploring lifestyle, environment, and genetics to help each patient achieve their ultimate health goals. Members have access to advanced medical treatments and technology, with care plans informed by data analytics and collaborative relationships. To learn more, visit forumhealth.com.

SOURCE Forum Health, LLC

https://forumhealth.com/

Read more:
Forum Health Welcomes Tara Scott, MD and First Location in Ohio - PRNewswire

Posted in Integrative Medicine | Comments Off on Forum Health Welcomes Tara Scott, MD and First Location in Ohio – PRNewswire

Page 602«..1020..601602603604..610620..»